

Follow-up Q & A Webinar: The Role of Shame in Opioid Use Disorders

Ashley Braun-Gabelman, Ph.D.
University Hospitals Case Medical Center
Cleveland, Ohio

Ashley Braun-Gabelman, Disclosures

- No Disclosures

*The contents of this activity may include discussion of off label or investigative drug uses.
The faculty is aware that is their responsibility to disclose this information.*

Planning Committee, Disclosures

AAAP aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, disclosure information from all planners, faculty and anyone in the position to control content is provided during the planning process to ensure resolution of any identified conflicts. This disclosure information is listed below:

The following developers and planning committee members have reported that they have no commercial relationships relevant to the content of this webinar to disclose: AAAP CME/CPD Committee Members Dean Krahn, MD, Kevin Sevarino, MD, PhD, Tim Fong, MD, Tom Kosten, MD, Joji Suzuki, MD; and AAAP Staff Kathryn Cates-Wessel, Miriam Giles, and Justina Andonian.

All faculty have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. The content of this CME activity has been reviewed and the committee determined the presentation is balanced, independent, and free of any commercial bias. Speakers must inform the learners if their presentation will include discussion of unlabeled/investigational use of commercial products.

Target Audience

- The overarching goal of PCSS-O is to offer evidence-based trainings on the safe and effective prescribing of opioid medications in the treatment of pain and/or opioid addiction.
- Our focus is to reach providers and/or providers-in-training from diverse healthcare professions including physicians, nurses, dentists, physician assistants, pharmacists, and program administrators.

Educational Objectives

- At the conclusion of this activity participants should be able to:
 - Define shame and differentiate between shame and guilt
 - Identify the relationship between shame and OUD
 - Discuss shame as it relates to particular subsets of people with OUD including:
 - People who inject heroin
 - Opioid-addicted pregnant women and mothers
 - Recognize indicators of shame in patients

Outline

- Definition of shame
- Case examples
- Recognizing and understanding shame in patients with OUD
- Treatment implications

What is shame?

- I feel intensely inadequate and full of self doubt
- I have an overpowering dread that my faults will be revealed in front of others
- At times I feel so exposed I wish the earth would open up and swallow me

What is shame?

“A powerful, but **unquestioned, conviction** that in some important way one is **flawed** and **incompetent** as a human being... The self-condemnation and self-loathing that shame precipitates are part and parcel of a pervasive, persistent, and destructive set of emotions that grips the sufferers with a crippling sense of terror and pessimism, preventing them from living harmoniously and confidently.”

(Goldberg, 1991)

What is shame?


- Exposure of a flawed self
 - Internal or external
- Competence: an expression of the ability, fitness, and capacity to live effectively and well
 - Shame involves feeling incompetent
- Primitive emotion that's adaptive function has been lost (Darwin, 1872)

Shame vs. Guilt

- Shame = Focus on self
- Guilt = Focus on specific behavior (Tangney & Dearing, 2002)
- I made a mistake vs. I am a mistake
- Shame and guilt often fused
- Shame-free guilt found to be adaptive
 - In prison sample, guilt found to be correlated with lower rates recidivism; shame correlated with higher rates (Hosser et al., 2008)

Compass of Shame


(Nathanson, 1992)



Secondary Reactions

- Anger
- Rage
- Resentment
- Jealousy
- Shamelessness
- Arrogance
- Self-glorification
- Aggressiveness
- Substance Use
- Self-harm

Cycle of Shame



Why aren't we better at working with shame?

“Pathological shame is both a crucial cause of human suffering, and at the same time, a silencing vehicle that keeps the misery a secret, unavailable to those who may be in a position to help.” (Goldberg, 1991)

- Hard to recognize
- Often masked by other emotions and/or behaviors
- Shame comes with hiding

Transference and Countertransference Issues

- Transference
 - Entering treatment may be shaming
 - Power differential in the therapeutic relationship
- Countertransference
 - What are our own experiences with and reactions to shame?
 - Patient may exhibit anger, blame, demands
 - Clinician may feel insecure, inadequate

Assessment Tools

- **Internalized Shame Scale** (ISS; Cook, 2001)
 - Used with SUD populations
- **Rosenberg's Self-Esteem Scale** (Rosenberg, 1965)
- **Test of Self-Conscious Affect** (Tangney, 1990)

Recognizing Shame



Nonverbal Indicators

- Gaze directed downward or averted
- Head lowered
- Some people blush
- Shoulders slumped
- Chest narrowed
- Face touching

Question

- Do you feel comfortable assessing for shame on the first medical assessment or do you wait for a couple of visits?
- What's the best way to initiate a conversation about shame in a 15 minute medical visit?

Answer

- If shame is noted, particularly non-verbal, this can be noted
- Therapeutic relationship is important before delving into shame
- What is the goal of raising the topic of shame in the medical visit? Is it necessary to determine level of care? Would it change level of care or treatment recommendations?
- No “quick fix” for shame. Requires longer-term commitment
- However, a non-judgmental environment and stance can help with state levels of shame and stigma and lead to a more open and honest conversation

Shame and Substance Use

- SUD vs. general population or other MH problems
(O'Connor et al., 1994)
 - SUD: Higher shame
 - SUD: Lower levels of adaptive guilt
- Higher levels of shame associated with relapse
(Wiechelt & Sales, 2001)
- Higher shame-prone children more likely to use drugs at age 18 (Tangney & Dearing, 2002; Stuewig et al., 2015)
- Shame about past drinking predicts future drinking
(Randles & Tracy, 2013)

Shame and Opioid Use

- Can be precursor and consequence; often cyclical
- Opioid use “protects” from the pain of shame
- People who use opioids and other drugs, highly avoidant of shame

Question

- How is it determined that shame predates OUD, and is not just a result of OUD?
- Often difficult to determine
- Patient's history may provide some hints
 - Attachment
 - Trauma/abuse history

Special OUD Populations

- **Heroin users** looked down on by people who use other opioids and other drugs
- **Injection drug users** looked down on by people who use heroin/other opiates/other drugs
 - Public vs. private injectors
- **MAT in NA**
- **Pregnant women and mothers**
 - MAT in pregnancy

Treatment Options

- 12-Step Programs
- Seeking Safety
- Matrix
- ACT

12-Step Programs

- Shame can interfere with a sense of belonging
 - Joining a group
- 12 steps: Shame can interfere or be improved
 - Step 4: Moral Inventory
 - Step 5: Admitting the nature of wrongs
 - Steps 8 & 9: Making amends

Seeking Safety

- Treatment for SUD + PTSD
- Focus on:
 - Compassion
 - Harsh vs. compassionate self-talk
 - Ways to increase compassion for self

Matrix

- Intensive outpatient treatment for people with stimulant use disorder (SAMHSA, 2006)
 - Can be applied to OUD
- Guilt and Shame module
- Differentiating between guilt and shame
- Asks patients to forgive themselves for past mistakes
 - Focuses more on guilt
 - Opens the discussion

ACT

(Luoma, Kohlenberg, Hayes, & Fletcher, 2012)

- ACT is not a quick-fix, but given time, a more effective treatment for shame
- An open, self-compassionate, values based approach

Case Vignette #1

- 60 y/o, African American, male Army veteran
- Polysubstance use (heroin, cocaine, etoh)
- PTSD (childhood physical, sexual; Military Sexual Trauma)
- > 30 arrests, prison 11 years manslaughter
- Wife and son died
- Self-reported anger, fear

Case #1 Questions

- What are the secondary reactions of shame in this patient?
- What issues may be contributing to his/her feelings of shame?
- What are some potential challenges the treating clinician might face?

Case Vignette #2

- 43 y/o, Latino male
- Chronic pain and prescription opioid use x20 years
- IV heroin use x3 years
- Married with 2 teenage sons
- Unemployed; wife = “breadwinner”
- Erectile dysfunction
- Wife: “I need a real man”

Case #2 Questions

- What issues may be contributing to his/her feelings of shame?
- What are appropriate treatment targets and goals?

Summary

- Shame = a conviction of a deeply flawed, inadequate self
- Shame vs. guilt
 - Self vs. behavior
 - Maladaptive vs. adaptive
- Nonverbal indicators of shame often more informative than self-report

Summary

- Shame is common among individuals with OUD and associated with use and relapse
- Within individuals with OUD, particular subgroups associated with shame include injection heroin users and pregnant women and mothers
- Shame should be a focus of OUD treatment

References

- Brown MZ, Linehan MM, Comtois KA, Murray A, & Chapman AL (2009). Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: A multi-modal analysis. *Behaviour research and therapy*, 47(10): 815-822.
- Bursten B (1973). Some narcissistic personality types. *International Journal of Psychoanalysis*, 54: 287-300.
- Castillo DT, Waldorf VA (2008). Ethical issues in the treatment of women with substance abuse. *The book of ethics: Expert guidance for professionals who treat addiction*, 101-114.
- Center for Substance Abuse Treatment. (2006). *Client's handbook: Matrix intensive outpatient treatment for people with stimulant use disorders*. Rockville, MD: Substance Abuse and Mental Health Services Administration.
- Cleaver H (2007). Georgian drug misusers switch to Western heroin substitute. *British Medical Journal*, 334(7598):821.
- Cook DR & Coccimiglio J (2001). *Internalized shame scale: Technical manual*. T. KostECKI-Dillon, & W. Wilson (Eds.). Multi-Health Systems.
- Darwin CR (1872). *The expression of the emotions in man and animals*. London: John Murray. 1st edition.
- Dearing RL, Stuewig J & Tangney JP (2005). On the importance of distinguishing shame from guilt: Relations to problematic alcohol and drug use. *Addictive behaviors*, 30(7): 1392-1404.
- Dickerson SS, Kemeny ME, Aziz N, Kim KH, & Fahey JL (2004). Immunological effects of induced shame and guilt. *Psychosomatic Medicine*, 66(1): 124-131.
- Goldberg C (1991). *Understanding Shame*. New Jersey: Jason Aronson Inc.
- Horowitz M (1981). Self-righteous rage. *Archives of General Psychiatry*, 38(11): 1233-1238.
- Hosser D, Windzio M, & Greve W (2008). Guilt and shame as predictors of recidivism: A longitudinal study with young prisoners. *Criminal Justice and Behavior*, 35(1), 138-152.
- Keltner D & Harker L (1998). The forms and functions of the nonverbal signal of shame. *Shame: Interpersonal behavior, psychopathology, and culture*, 78-98.

References

- Luoma, J. B., Kohlenberg, B. S., Hayes, S. C., & Fletcher, L. (2012). Slow and steady wins the race: a randomized clinical trial of acceptance and commitment therapy targeting shame in substance use disorders. *Journal of consulting and clinical psychology, 80*(1), 43.
- Nathanson DL (1992). *Shame and pride: Affect, sex, and the birth of the self*. New York: WW Norton & Company.
- Randles D & Tracy JL (2013). Nonverbal displays of shame predict relapse and declining health in recovering alcoholics. *Clinical Psychological Science, 1*(2): 149-155.
- Rhodes T, Watts L, Davies S, Martin A, Smith J, Clark D, ... & Lyons M (2007). Risk, shame and the public injector: A qualitative study of drug injecting in South Wales. *Social Science & Medicine, 65*(3), 572-585.
- Rosenberg M (1965). *Society and the adolescent self-image*. New Jersey: Princeton University Press.
- Rycroft C (1968). *A critical dictionary of psychoanalysis*. London: Thomas Nelson and Sons.
- Stuewig J, Tangney JP, Kendall S, Folk JB, Meyer CR, & Dearing RL (2015). Children's proneness to shame and guilt predict risky and illegal behaviors in young adulthood. *Child Psychiatry & Human Development, 46*(2): 217-227.
- Tangney JP (1990). Assessing individual differences in proneness to shame and guilt: Development of the Self-Conscious Affect and Attribution Inventory. *Journal of Personality and Social Psychology, 59*: 102-111.
- Tangney JP & Dearing RL (2002). *Shame and guilt*. New York: Guilford Press.
- Tangney JP, Wagner P, & Gramzow R (1992). Proneness to shame, proneness to guilt, and psychopathology. *Journal of abnormal psychology, 101*(3): 469.
- O'Connor LE, Berry JW, Inaba D, Weiss J, & Morrison A. (1994). Shame, guilt, and depression in men and women in recovery from addiction. *Journal of substance abuse treatment, 11*(6): 503-510.
- Varty K & Alwyn T (2011). Women's experiences of using heroin substitute medication in pregnancy. *British Journal of Midwifery, 19*(8): 507 – 514.
- Wiechelt SA & Sales E (2001). The role of shame in women's recovery from alcoholism: The impact of childhood sexual abuse. *Journal of Social Work Practice in the Addictions, 1*(4): 101-116.

PCSS-O Colleague Support Program and Listserv

- PCSS-O Colleague Support Program is designed to offer general information to health professionals seeking guidance in their clinical practice in prescribing opioid medications.
- PCSS-O Mentors comprise a national network of trained providers with expertise in **addiction medicine/psychiatry and pain management**.
- Our mentoring approach allows every mentor/mentee relationship to be unique and catered to the specific needs of both parties.
- The mentoring program is available at no cost to providers.

For more information on requesting or becoming a mentor visit:

www.pcss-o.org/colleague-support

- **Listserv:** A resource that provides an “Expert of the Month” who will answer questions about educational content that has been presented through PCSS-O project. To join email: pcss-o@aaap.org.



PCSS-O is a collaborative effort led by American Academy of Addiction Psychiatry (AAAP) in partnership with: Addiction Technology Transfer Center (ATTC), American Academy of Neurology (AAN), American Academy of Pain Medicine (AAPM), American Academy of Pediatrics (AAP), American College of Physicians (ACP), American Dental Association (ADA), American Medical Association (AMA), American Osteopathic Academy of Addiction Medicine (AOAAM), American Psychiatric Association (APA), American Society for Pain Management Nursing (ASPMN), International Nurses Society on Addictions (IntNSA), and Southeast Consortium for Substance Abuse Training (SECSAT).

For more information visit: www.pcss-o.org

For questions email: pcss-o@aaap.org



Twitter: [@PCSSProjects](https://twitter.com/PCSSProjects)